Amedisys Reports Fourth Quarter and Year End 2018 Financial Results Issues 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Amedisys (AMED) PT Lowered to $124 at Craig-Hallum
February 28, 2019 3:52 PM ESTCraig-Hallum analyst Kevin Ellich lowered the price target on Amedisys (NASDAQ: AMED) to $124.00 (from $132.00) while maintaining a Hold rating.
Ellich notes FY19 guidance was lower partially due to CCH integration.
... MoreAmedisys (AMED) Tops Q4 EPS by 6c, Offers FY Guidance
February 27, 2019 5:02 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $0.91, $0.06 better than the analyst estimate of $0.85. Revenue for the quarter came in at $434.4 million versus the consensus estimate of $427.51 million.
GUIDANCE:
Amedisys sees FY2019 EPS of $3.98-$4.09, versus the consensus of $4.08. Amedisys sees... More
